Technical Data

BD investing $1.2 billion into manufacturing of prefillable injection systems

Download

PDF 1.0 MB

BD investing $1.2 billion into manufacturing of prefillable injection systems

BD has plans to invest approximately $1.2 billion over a 4-year period. The investment will fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs - including complex biologics, vaccines and small molecules -. A new manufacturing facility in Europe is expected to be operational by the end of 2023.

More information available in our datasheet.



Other Content from SAS BECTON DICKINSON FRANCE